Mizuho analyst Ann Hynes raised the firm’s price target on Elevance Health (ELV) to $413 from $400 and keeps an Outperform rating on the shares. The firm updated targets in the healthcare facilities and managed care group as part of a Q4 preview. Mizuho’s physician survey indicated healthcare utilization growth trends decelerated sequentially despite easier year-over-year comps, which could indicate trend is peaking, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health upgraded to Outperform from Peer Perform at Wolfe Research
- Trump Trade: Trump says Venezuela to give U.S. up to 50M barrels of oil
- Elevance Health price target raised to $424 from $403 at Wells Fargo
- Trump says he will meet with 14 health insurers in a few days
- Elevance Health price target raised to $431 from $412 at Bernstein